HP-03-004 The role of testosterone replacement therapy on metabolic disorders in patient with type 2 diabetes mellitus and androgen deficiency

Background: In men with low levels of testosterone in the blood, it is believed that the symptoms can be regarded as an association between testosterone deficiency syndrome and related comorbidities. Aim: to investigate the effectiveness of testosterone therapy in patients with type 2 diabetes (T2D) and androgen deficiency. Materials and methods: Testosterone replacement therapy was carried out in 26 men with T2D and clinically or laboratory-confirmed androgen deficiency. The age of the subjects ranged from 35 to 69 years old. Laboratory studies included determinations of the concentration of the hormones estradiol, luteinizing hormone (LH), and prostate-specific antigen (PSA). The observation period was 9 months. Results: The average level of total blood testosterone in the subjects before treatment was 9.4 mol/l and was likely lower than that of the control group (19.3 ± 1.6 nmol/l). The levels of total testosterone in the subjects ranged from 3.9 nmol/l to 10.7 nmol/l, and hormone levels measuring less than 8.0 nmol/l were observed in only 11 patients. After a course of testosterone replacement therapy, a stabilization in total testosterone levels at the level of reference values (as compared to the start of treatment) was observed in the blood of men with T2D after 9 months of observation and the administration of the fourth injection (16.83 ± 0.75 nmol/l). Conclusion: The use of long-acting injectable testosterone undecanoate leads to normalization of total testosterone levels in the blood of men with T2D and androgen deficiency, and LH levels in these patients are unlikely to change.

Download Full-text

Type 2 Diabetes Mellitus Associated with Obesity (Diabesity). The Central Role of Gut Microbiota and Its Translational Applications

Nutrients ◽

10.3390/nu12092749 ◽

2020 ◽

Vol 12 (9) ◽

pp. 2749 ◽

Cited By ~ 1

Author(s):

Miguel A. Ortega ◽

Oscar Fraile-Martínez ◽

Irene Naya ◽

Natalio García-Honduvilla ◽

Melchor Álvarez-Mon ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Gut Microbiota ◽

Metabolic Disorders ◽

Health Concern ◽

Public Health Concern ◽

Wide Range

Obesity is a condition of rising prevalence worldwide, with important socioeconomic implications, being considered as a growing public health concern. Frequently, obesity brings other complications in addition to itself—like Type 2 Diabetes Mellitus (T2DM)—sharing origin, risk factors and pathophysiological mechanisms. In this context, some authors have decided to include both conditions as a unique entity known as “diabesity”. In fact, understanding diabesity as a single disease is possible to maximise the benefits from therapies received in these patients. Gut microbiota plays a key role in individual’s health, and their alterations, either in its composition or derived products are related to a wide range of metabolic disorders like T2DM and obesity. The present work aims to collect the different changes reported in gut microbiota in patients with T2DM associated with obesity and their possible role in the onset, development, and establishment of the disease. Moreover, current research lines to modulate gut microbiota and the potential clinical translation derived from the knowledge of this system will also be reviewed, which may provide support for a better clinical management of such a complex condition.

Download Full-text

The role of inflammation in the development of metabolic disorders in patients with arterial hypertension

Siberian Medical Journal ◽

10.29001/2073-8552-2019-34-3-45-52 ◽

2019 ◽

Vol 34 (3) ◽

pp. 45-52

Author(s):

L. V. Zhuravlyova ◽

M. V. Kulikova

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Arterial Hypertension ◽

Metabolic Disorders ◽

Developed Countries ◽

The World ◽

The Developed Countries

In recent years, the comorbid course of cardiovascular diseases, primarily arterial hypertension with impaired carbohydrate tolerance or type 2 diabetes mellitus, is becoming increasingly important in the developed countries of the world. In this regard, the need for a more detailed study of the general mechanisms of the development of arterial hypertension, pre-diabetes, and type 2 diabetes mellitus, namely inflammation, is increasing. There are many studies that investigate the role of inflammation in hypertension and associated glucometabolic disorders, but the exact mechanisms by which activated immune cells lead to the development and maintenance of these conditions remain to be seen. Obtaining new data in this area may contribute to a deeper understanding of cardiometabolic disorder pathogenesis. It may allow to predict the progression of these disorders at the early stages and to develop effective preventive and therapeutic tactics for their correction.

Download Full-text